worldwide offices | contact | help | sitemap
Diseases & products
Diseases & products home
About Novartis Vaccines
About Novartis Vaccines home
Novartis Vaccines history
Novartis Vaccines educational grants
Business development home
About the Business Development & Licensing group
Our areas of interest
Meningococcal Disease Press Kit
Seasonal Influenza Press Kit
Cultures & values
Diversity & inclusion
Novartis Bexsero® vaccine approved by FDA for the prevention of meningitis B, a leading cause of bacterial meningitis in the US.
Safety and efficacy of Fluad vaccinations in Italy.
Novartis announces divestiture of influenza vaccines business to CSL for USD 275 million.
Novartis vaccine Bexsero® sees high uptake in first large-scale public vaccination program to help protect against devastating meningitis B.
Novartis begins shipment of seasonal influenza vaccines to US market for the 2014-2015 season.
Novartis submits application to the FDA for meningitis B vaccine candidate Bexsero® to help protect US adolescents and young adults.
Vaccines US • Vaccines Germany • Vaccines Italy
See stock performance
Novartis Vaccines wins the Best Pharma Company award.
Novartis ranked no. 11 on Science's Top 20 Employers list.